Deep brain stimulation in early-stage Parkinson diseaseMallory L. Hacker, David Charles, Peter E. Konrad et al.|Neurology|2020Cited by 141
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical TrialMichael Brownstein, Stephanie Lowenhaupt, Elaine Sperin et al.|Journal of Clinical Medicine|2020Cited by 32